Vesicoureteral reflux and continuous prophylactic antibiotics

Area of Science:

• Pediatric Urology
• Infectious Diseases
• Nephrology

Background:

• Vesicoureteral reflux (VUR) management requires individualized approaches considering infection risk, renal scarring, and patient factors.
• Non-surgical management, including continuous antibiotic prophylaxis (CAP), is common for VUR in children, but its efficacy is debated.
• Previous studies on CAP efficacy have limitations, including design flaws and small sample sizes.

Purpose of the Study:

• To review the controversy surrounding VUR management strategies.
• To highlight the findings of the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial.
• To discuss the impact of RIVUR trial results on understanding CAP in VUR management.

Main Methods:

• Review of existing literature and the RIVUR trial.
• Analysis of factors influencing VUR management decisions.
• Discussion of the implications of recent trial data.

Main Results:

• The RIVUR trial provided significant data on the efficacy of CAP in preventing recurrent urinary tract infections (UTIs) in children with VUR.
• Findings suggest that the benefits of CAP may be less pronounced than previously assumed, especially in certain patient subgroups.
• The study addressed limitations of prior research, offering clearer insights into CAP's role.

Conclusions:

• The RIVUR trial challenges the routine use of CAP for all children with VUR.
• Management strategies for VUR should be refined based on updated evidence, emphasizing risk stratification and individualized care.
• Further research may be needed to optimize VUR treatment protocols.